J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Compensation Committee of the Board of Directors of the Company has, on November 17, 2022, allotted 18,730 fully paid up equity shares of Rs. 2/- each of the Company, to certain employees on exercise of stock options granted to them pursuant to JBCPL Employee Stock Option Scheme, 2021. J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Audio Recording Of Investors/Analysts Call With Management
Disclosure under regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Audio recording of Investors/analysts call with Management J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting of extract of consolidated financial results for quarter ended on September 30, 2022
JB Chemicals & Pharma Q2 PAT up 13% to Rs 111 cr; revenue at Rs 809 cr
JB Chemicals & Pharmaceuticals has reported 13 per cent rise in profit after tax at Rs 111 crore for the second quarter ended September 30, 2022. The drug firm had logged a profit after tax (PAT) of Rs 98 crore in July-September period of previous fiscal year. Revenue rose to Rs 809 crore in the period under review as compared with Rs 593 crore in the year-ago quarter, it said in a statement. "Our market-beating performance in domestic business was sustained through growth in our organic portfolio, with big brands getting bigger; and significant demand acceleration in acquired brands which have seamlessly transitioned in a short period," company CEO and Wholetime Director Nikhil Chopra said. The momentum in the international business continued across markets, with all three of the company's verticals performing well, he added. "Our strategic focus on key brands, segments and geographies is resulting in a consistent, sustained revenue growth. "And this growth, along with... J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of duplicate share certificate J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Investor Presentation
investors/analysts presentation the Company proposes to on performance of the Company for the quarter ended on September 30, 2022. J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Enclosed please find press release the Company proposes to issue on unaudited consolidated financial results for the quarter ended on September 30, 2022. J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors - Unaudited Financial Results For The Quarter Ended September 30, 2022
In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find: 1. Unaudited standalone financial results for the quarter ended on September 30, 2022 accompanied by limited review report. 2. Unaudited consolidated financial results for the quarter ended on September 30, 2022 accompanied by limited review report. These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 4.18 p.m. and concluded at 6.12 p.m. J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investors/ Analysts call with Management J.B.CHEMICALS & PHARMACEUTICALS LTD. - 506943 - Board Meeting Intimation for Unaudited Financial Results For The Quarter And Half Year Ended On September 30, 2022
J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 ,inter alia, to consider and approve unaudited financial results for the quarter and half year ended on September 30, 2022